ARL5B and neoplasm: By terminal sacrifice, tumors from the shARL5B group displayed significantly decreased tumor volume and mass compared to controls (both p < 0.001; Figure 2G,H), with ARL5B protein levels in tumor tissues confirming effective knockdown between the two groups (p < 0.05; Figure 2I; Figure S1C, Supporting Information).